254 Results
The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.
Journal of Thoracic Oncology Study: VerStrat provides oncologists with more information to personalize therapy for their patients.
Analysis showed that the VeriStrat test was able to identify patients more likely to have a slower progression of disease with select treatments.
Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.
Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.
Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.
VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.
Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.
Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).